Patent · US Active

Vaccine for prophylaxis or treatment of an allergen-driven airway pathology

US10653765B2 · kind B2 · utility

3Cited by

0References

6Claims

0Family size

Inventors

Camille Locht · Wannehain, FR
Bernard Mahon · Maynooth, IE
Heather Kavanagh · Dublin, IE

Key dates

Filing date	Aug 9, 2019
Grant date	May 19, 2020
Priority date	—
Expiry date	Aug 9, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/544
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.